التفاصيل البيبلوغرافية
| العنوان: |
DataSheet_1_Peripheral blood marker of residual acute leukemia after hematopoietic cell transplantation using multi-plex digital droplet PCR.pdf |
| المؤلفون: |
M. Stanojevic, M. Grant, S. K. Vesely, S. Knoblach, C. G. Kanakry, J. Nazarian, E. Panditharatna, K. Panchapakesan, R. E. Gress, J. Holter-Chakrabarty, Kirsten M. Williams |
| سنة النشر: |
2022 |
| المجموعة: |
Frontiers: Figshare |
| مصطلحات موضوعية: |
Immunology, Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies), Autoimmunity, Cellular Immunology, Humoural Immunology and Immunochemistry, Immunogenetics (incl. Genetic Immunology), Innate Immunity, Transplantation Immunology, Tumour Immunology, Immunology not elsewhere classified, Genetic Immunology, Animal Immunology, Veterinary Immunology, minimal residual disease, digital droplet PCR, acute leukemia, relapse, hematopoietic cell transplantation |
| الوصف: |
Background Relapse remains the primary cause of death after hematopoietic cell transplantation (HCT) for acute leukemia. The ability to identify minimal/measurable residual disease (MRD) via the blood could identify patients earlier when immunologic interventions may be more successful. We evaluated a new test that could quantify blood tumor mRNA as leukemia MRD surveillance using droplet digital PCR (ddPCR). Methods The multiplex ddPCR assay was developed using tumor cell lines positive for the tumor associated antigens (TAA: WT1, PRAME, BIRC5), with homeostatic ABL1. On IRB-approved protocols, RNA was isolated from mononuclear cells from acute leukemia patients after HCT (n = 31 subjects; n = 91 specimens) and healthy donors (n = 20). ddPCR simultaneously quantitated mRNA expression of WT1, PRAME, BIRC5, and ABL1 and the TAA/ABL1 blood ratio was measured in patients with and without active leukemia after HCT. Results Tumor cell lines confirmed quantitation of TAAs. In patients with active acute leukemia after HCT (MRD+ or relapse; n=19), the blood levels of WT1/ABL1, PRAME/ABL1, and BIRC5/ABL1 exceeded healthy donors (p<0.0001, p=0.0286, and p=0.0064 respectively). Active disease status was associated with TAA positivity (1+ TAA vs 0 TAA) with an odds ratio=10.67, (p=0.0070, 95% confidence interval 1.91 – 59.62). The area under the curve is 0.7544. Changes in ddPCR correlated with disease response captured on standard of care tests, accurately denoting positive or negative disease burden in 15/16 (95%). Of patients with MRD+ or relapsed leukemia after HCT, 84% were positive for at least one TAA/ABL1 in the peripheral blood. In summary, we have developed a new method for blood MRD monitoring of leukemia after HCT and present preliminary data that the TAA/ABL1 ratio may may serve as a novel surrogate biomarker for relapse of acute leukemia after HCT. |
| نوع الوثيقة: |
dataset |
| اللغة: |
unknown |
| Relation: |
https://figshare.com/articles/dataset/DataSheet_1_Peripheral_blood_marker_of_residual_acute_leukemia_after_hematopoietic_cell_transplantation_using_multi-plex_digital_droplet_PCR_pdf/21226646 |
| DOI: |
10.3389/fimmu.2022.999298.s001 |
| الاتاحة: |
https://doi.org/10.3389/fimmu.2022.999298.s001
https://figshare.com/articles/dataset/DataSheet_1_Peripheral_blood_marker_of_residual_acute_leukemia_after_hematopoietic_cell_transplantation_using_multi-plex_digital_droplet_PCR_pdf/21226646 |
| Rights: |
CC BY 4.0 |
| رقم الانضمام: |
edsbas.45A3A0F7 |
| قاعدة البيانات: |
BASE |